Connect to other sites within the UBM Medica Network
The FDA has approved panobinostat (Farydak), in combination with bortezomib and dexamethasone, for treating patients with multiple myeloma.
ENDEAVOR: Carfilzomib Doubles PFS in Relapsed Myeloma
Treatment with carfilzomib and dexamethasone doubled the PFS in relapsed multiple myeloma patients compared with treatment with bortezomib and dexamethasone.
Prior Knowledge of MGUS Linked to Improved Multiple Myeloma Survival
Multiple myeloma patients had better overall survival if they had prior knowledge of having monoclonal gammopathy of undetermined significance.
FDA Approves Panobinostat for Multiple Myeloma
FDA Approves Front-Line Lenalidomide for Multiple Myeloma
The FDA has expanded the use of oral lenalidomide in multiple myeloma to include its use in combination with dexamethasone for newly diagnosed patients.
Frailty Score Predicts Survival in Elderly Myeloma Patients
A scoring system that measured frailty in elderly patients with multiple myeloma was able to accurately predict mortality and risk of toxicity.
Myeloma Working Group Releases Statement on Use of MRI
The International Myeloma Working Group recently published a series of consensus statements discussing the use of MRI in the treatment of multiple myeloma.
Higher Bortezomib Dose Upped Multiple Myeloma Survival
A new trial reported improved overall survival in myeloma patients who received a higher bortezomib dose as part of a bortezomib/melphalan/prednisone regimen.
By clicking Accept, you agree to become a member of the UBM Medica Community.